31 related articles for article (PubMed ID: 6323321)
1. Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Friedel HA; Campoli-Richards DM; Goa KL
Drugs; 1989 Apr; 37(4):491-522. PubMed ID: 2661196
[TBL] [Abstract][Full Text] [Related]
2. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
Campoli-Richards DM; Brogden RN
Drugs; 1987 Jun; 33(6):577-609. PubMed ID: 3038500
[TBL] [Abstract][Full Text] [Related]
3. Antibacterial activity and kill kinetics of ampicillin/sulbactam (CP-45899) combinations against Escherichia coli and Klebsiella aerogenes.
Fuglesang JE; Bergan T
Infection; 1984; 12(1):46-50. PubMed ID: 6323321
[TBL] [Abstract][Full Text] [Related]
4. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
Traub WH; Leonhard B
Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
[TBL] [Abstract][Full Text] [Related]
5. Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae.
Shungu DL; Ponticas S; Gill CJ
Clin Ther; 1989; 11(3):315-8. PubMed ID: 2663161
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
7. Sulbactam: biochemical factors involved in its synergy with ampicillin.
Labia R; Morand A; Lelievre V; Mattioni D; Kazmierczak A
Rev Infect Dis; 1986; 8 Suppl 5():S496-502. PubMed ID: 3025996
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial kinetics of ampicillin against Escherichia coli under simulated in vivo conditions.
Fuglesang JE; Bergan T
Infection; 1982 Jan; 10(1):31-4. PubMed ID: 7040252
[TBL] [Abstract][Full Text] [Related]
9. An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions.
Bergan T; Carlsen IB; Fuglesang JE
Infection; 1980; Suppl 1():096-10. PubMed ID: 6772578
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial activity and kill kinetics of amoxicillin-clavulanic acid combinations against Escherichia coli and Klebsiella aerogenes.
Fuglesang JE; Bergan T
Infection; 1983; 11(6):329-35. PubMed ID: 6365790
[TBL] [Abstract][Full Text] [Related]
11. [Beta lactamase inhibitors, a new start of antibiotic therapy].
Wundt W; Baumgärtner M
Dtsch Med Wochenschr; 1982 Aug; 107(34):1285-9. PubMed ID: 6286267
[No Abstract] [Full Text] [Related]
12. Inhibitory activity and bactericidal kinetics of mecillinam/ampicillin combinations against Enterobacteriaceae, Pseudomonas and Acinetobacter.
Fuglesang JE; Bergan T; Bielecki T; Naterstad A; Namork E
Infection; 1981; 9(6):290-5. PubMed ID: 6277795
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
